Streetbeat News

Products Services

HALO

Halozyme Therapeutics reported positive topline data from the ADHERE study evaluating VYVGART Hytrulo with ENHANZE in adults with chronic inflammatory demyelinating polyneuropathy. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 4:38 pm

HALO

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced positive topline data from the ADHERE study evaluating VYVGART® Hytrulo with ENHANZE® in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint demonstrating a significantly lower risk of relapse with VYVGART® Hytrulo compared to placebo. This is the second successful outcome for VYVGART Hytrulo this year, with two additional study readouts expected in the fourth quarter.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 4:37 pm

ATVI

EA

MSFT

WBD

Microsoft Store has launched its Ultimate Game Sale, offering up to 90% discounts on select Xbox and PC games, PC accessories, and Xbox console bundles until July 31. Some of the highlighted titles include Electronic Arts' FIFA 23, NBA 2K23, and Forza Horizon 5 Premium Edition. Other discounts include popular titles such as Star Wars Jedi: Survivor, Warner Bros. Games' Hogwarts Legacy Deluxe Edition, Activision Blizzard's Call of Duty: Modern Warfare II, and others. No special discounts on Game Pass are currently available, but new subscribers can take advantage of Microsoft's recent reintroduction of the $1 first-month trial.

Portfolio Pulse from Franca Quarneti

July 17, 2023 | 4:32 pm

VIRI

Virios Therapeutics Inc announced that its combination therapy of valacyclovir and celecoxib showed significant improvements in patients with Long-COVID. The company plans to meet with the FDA in 2023 to discuss an investigational new drug application. Despite the positive news, VIRI shares are down 21.10%.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 4:20 pm

IVVD

Invivyd Inc (NASDAQ:IVVD) has released additional initial data from its ongoing Phase 1 clinical trial of its lead investigational monoclonal antibody (mAb) candidate, VYD222. The data shows that a single administration of VYD222 was generally well-tolerated at all three dose levels tested, with no serious adverse events reported. The company intends to use these analyses to further inform its VYD222 dosing strategy.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 4:15 pm

VIRI

Virios Therapeutics announced data showing improvement in multiple Long-Covid symptoms following treatment with a combination of Valacyclovir and Celecoxib in a proof of concept study. However, the company's shares are trading lower.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 4:12 pm

FSR

Fisker Inc (NYSE:FSR) plans to produce 100 Fisker Extreme Vigyan Edition all-electric SUVs for the Indian market, with deliveries expected to begin in Q4 2023. The pricing is expected to match Europe, where the Fisker Ocean Extreme is priced at €69,950 in Germany. Fisker's shares are trading higher by 3.8% at $6.41.

Portfolio Pulse from Shivani Kumaresan

July 17, 2023 | 4:07 pm

NVDA

Nvidia's shares reached a record high of $480.88, marking a year-to-date increase of over 200%. The company's GPUs have been used in training OpenAI's ChatGPT. The stock may experience a slight setback before reaching the $500 milestone, but this is seen as a strategic pause for future growth.

Portfolio Pulse from Zaheer Anwari

July 17, 2023 | 4:06 pm

SNY

Scribe Therapeutics has expanded its collaboration with Sanofi to advance in vivo genetic medicines for sickle cell and other genomic diseases. Scribe will receive $40M upfront, with the potential for more than $1.2B in milestones across all programs. The collaboration will leverage Scribe's CRISPR X-Editing (XE) technologies and Sanofi's capabilities in non-viral delivery to address sickle cell disease.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 3:53 pm

LIXT

LIXTE Biotechnology announced results of its collaboration with the Netherlands Cancer Institute, showing that LB-100 enhanced the effectiveness of immunotherapy and chemotherapy. This news led to a rise in LIXTE's share prices.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 3:50 pm